



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:

A61K 38/45, 47/48, 48/00, C07K 16/46, C12N 9/10, C07K 19/00

(11) International Publication Number:

WO 97/27871

(43) International Publication Date:

7 August 1997 (07.08.97)

(21) International Application Number:

PCT/EP97/00426

A1

(22) International Filing Date:

31 January 1997 (31.01.97)

(30) Priority Data:

96101469.3 2 February 1996 (02.02.96) EP

(34) Countries for which the regional or international application was filed:

DE et al.

(71) Applicant (for all designated States except US): BOEHRINGER MANNHEIM GMBH [DE/DE]; Sandhofer

Strasse 112, D-68305 Mannheim (DE).

(72) Inventors; and

'5) Inventors/Applicants (for US only): VON EICHEL-STREIBER, Christoph [DE/DE]; Bingerweg 15, D-55444 Schweppenhausen (DE). BOQUET, Patrice [FR/FR]; 44, avenue de la Marme, F-06107 Nice (FR). THELESTAM, Monica [SE/SE]; Hagalundsg. 4013, S-17150 Solna (SE).

BOEHRINGER MANNHEIM ommon Representative: GMBH; Werk Penzberg, Abt. RE-TB (Patentabteilung), Postfach 11 52, D-82372 Penzberg (DE).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT. RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of

(54) Title: -METHOD OF INACTIVATION OF RAS SUBFAMILY PROTEINS AND AGENTS THEREFOR

(57) Abstract

The invention comprises a method of treating a patient with a disorder, characterized by an activating mutation in the Ras protooncogene, comprising contacting cells of said patient with a protein having the toxic activity of Clostridium sordellii toxin LT under conditions favoring inactivating of Ras by glucosylation of Ras' threonine 35 in said cell. Said protein preferably is an immunotoxin which contains as a toxic domain the catalytic domain of toxin LT.